Tabula Rasa HealthCare — Merger or Acquisition (September 2017)
22 slides from Tabula Rasa HealthCare's merger presentation, Sep 7, 2017

Slide 1: Legal Disclosure
Legal Disclosure Forward-looking statements This presentation contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements as defined by the Private Securities Litigation Reform Act o

Slide 2: Management presenters
Management presenters Calvin H. Knowlton, PhD CEO & Chairman of the Board Brian W. Adams Chief Financial Officer Orsula V. Knowlton, PharmD President & Director 3 Kevin P. Boesen, PharmD CEO & Founder

Slide 3: Tabula Rasa at a glance
Tabula Rasa at a glance Founded 2009 HQ in Moorestown, NJ ~300 employees 140 clients 98% revenue retention IP Patents & Significant Science that is difficult to replicate Multi-billion TAM Proprietary Medication Risk Mitigation Matrix® Tabula Rasa has developed a proprietary software platform that r

Slide 4: SinfoníaRx at a glance
SinfoníaRx at a glance Medication Risk Mitigation 5 SinfoníaRx is the leading MTM provider, offering a full suite of MTM services to meet the needs of health plans and their patients Founded at the University of Arizona in 2006 by Dr. Kevin Boesen, a faculty member at the College of Pharmacy In 2013

Slide 5: SinfoníaRx is a strong strategic and cultural fit
SinfoníaRx is a strong strategic and cultural fit Medication Risk Mitigation 6 SinfoníaRx offers a best in class Medication Therapy Management (MTM) solution and complements Tabula Rasa’s Enhanced MTM Similar focus on improving medication therapies Creates ability to leverage Tabula Rasa’s MRM Matri

Slide 6: SinfoniaRx is a strong strategic and cultural fit
SinfoniaRx is a strong strategic and cultural fit Y SinfoniaRx offers a best in class Medication Therapy Management (MTM) solution and complements Tabula Rasa’s Enhanced MTM Y Similar focus on improving medication therapies Y Creates ability to leverage Tabula Rasa’s MRM Matrix and Medication Risk S

Slide 7: SinfoníaRx History
Founded by Dr. Kevin Boesen in 2006 at the University of Arizona while a faculty member at the College of Pharmacy In 2013, the company was spun out of the University of Arizona to a group of Arizona investors and former public company leaders creating SinfoníaRx to further develop MTM solutions for

Slide 8: The Leading Provider of MTM Solutions
The Leading Provider of MTM Solutions Services Full CPPA accredited MTM programs Software as a Service solution Clinic-based and telemedicine models Contracted Call Centers University of Arizona (Tucson and Phoenix) The Ohio State University SinfoníaRx – Florida SinfoníaRx – Texas SinfoníaRx special

Slide 9: SinfoníaRx solution suite
CMS Medicare Part D Required MTM Program SinfoníaRx’s MTM program meets CMS Requirements Comprehensive Medication Reviews (CMRs) Targeted Medication Reviews (TMR) and outreach STAR Improvement Program Intervention targeting for patients not qualified for the CMS required MTM program STAR rating perf

Slide 10: Complementary solutions and significant cross selling opportunity
Complementary solutions and significant cross selling opportunity Customers include: Part D providers Commercial Health Plans Medicaid Pharmacies (SaaS) No customer overlap with Tabula Rasa’s legacy customers Ability to offer Tabula Rasa’s medication risk identification, stratification, risk score,

Slide 11: Complementary solutions and significant cross selling opportunity
Complementary soluti and significant cross selling opportunity SinfoniaRx Client Growth cu 2013 - 2017 a 7 . Part D providers a ” 5 Commercial Health Plans | [6 Medicaid : | | [| Pharmacies (SaaS) * 2013 2014 2015 2016 2017 * Nocustomer overlap with Tabula Rasa’s legacy customers * Ability to offer

Slide 12: Financial rationale
Financial rationale Medication Risk Mitigation 13 Incremental expected financial contributions to 2017 (Sept-Dec) Similar expected revenue growth and profitability as TRHC Adds scale to service revenue Service revenue is expected to represent 30% of total revenue in 2018 compared to approximately 20

Slide 13: Sinfonia historical and expected financials
Sinfonia historical and expected financials Medication Risk Mitigation 14 $21.0 $27.1 $31.0 2015 2016 2017E Revenue ($M) $2.1 $3.0 $4.5 2015 2016 2017E Adjusted EBITDA ($M) 26% 29% 33% 2015 2016 2017E Gross Margin 10% 11% 15% 2015 2016 2017E Adjusted EBITDA Margin

Slide 14: Transaction terms
Transaction terms Medication Risk Mitigation 15 Price $35 million cash / 520,833 shares of common stock Financing Simultaneous with deal closing, Tabula Rasa has increased senior credit facility to $40 million Potential Earn Outs Up to $85 million - 50% cash and 50% stock (subject to adjustment) -pe

Slide 15: Updated Tabula Rasa Financial Outlook
Updated Tabula Rasa Financial Outlook 16 $116m - $118m $126m - $128m Unable to estimate Net Income or Loss until purchase accounting for the transaction is complete. Expected update with Q3 reporting. $15.5m - $16.5m $17.5m - $18.5m Revenue Net Income (Loss) Adjusted EBITDA Medication Risk Mitigatio

Slide 16: Updated Tabula Rasa Financial Outlook
Updated Tabula Rasa Financial Outlook 2017 Gui Revenue $116m-$118m $126m-$128m Unable to estimate Net Income or Loss until purchase accounting for the transaction is complete. Expected update with Q3 reporting. Net Income (Loss) Adjusted EBITDA $15.5m -$16.5m $17.5m - $18.5m TABULARASA a Medication

Slide 17: Combination Creates Market Leading Position
Flexible and highly scalable service delivery platform Services performed go well beyond traditional MTM requirements Track record of meeting 100% of client goals Recent expansion of markets and services beyond MTM Combination Creates Market Leading Position Validated Medication Risk Score Proprieta

Slide 18: Combination Creates Market Leading Position
Combination Creates Market Leading Position a va TABULARASA SS Validated Medication Risk Score Flexible and highly scalable service delivery platform Proprietary medication risk identification and stratification tools Services performed go well beyond traditional MTM requirements Demonstrated reduct

Slide 19: Questions
"s TABULARASA Questions

Slide 20: Reconciliation of net loss to Adjusted EBITDA
Tabula Rasa HealthCare, Inc. Reconciliation of net loss to Adjusted EBITDA Reconciliation of net loss to Adjusted EBITDA Net loss $ (6.3) $ (2.9) Add: Change in fair value of warrant liability (0.6) 2.8 Interest expense 4.4 5.9 Loss on extinguishment of debt 6.4 — Income tax expense 0.5 0.3 Deprecia

Slide 21: Reconciliation of Adjusted EBITDA to Net income (loss) - SinfoniaRx
Reconciliation of Adjusted EBITDA to Net income (loss) - Unaudited Medication Risk Mitigation 22 SinfoniaRx Business (UNAUDITED): (in millions) Year Ended December 31, 2016 2015 Net income (loss) $ (1.5) $ (0.4) Add: Interest expense — — Income tax expense (0.2) (0.3) Depreciation and amortization 1

Slide 22: Reconciliation of Adjusted EBITDA to Net income (loss) - SinfoniaRx
Reconciliati SinfoniaRx Business (UNAUDITED): (in millions) Net income (loss) Add: Interest expense Income tax expense Depreciation and amortization Stock-based compensation expense Management fee expenses Adjusted EBITDA, of Adjusted EBIT| to Net income (loss) - Unaudited (1.5) $ (0.4) (0.2) (0.3)
Source: SEC EDGAR · 8-K filed Sep 7, 2017



